Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery

Plain-language guide to PMID 12144941 (2002): placebo-controlled controlled clinical trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 24 patients.

Key Facts

PMID: 12144941
Journal: European journal of pharmacology
Year: 2002
Study type: Controlled Clinical Trial
Authors: Broglio F et al. (10 authors)
DOI: 10.1016/s0014-2999(02)01934-9

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone), published as a controlled clinical trial.

Growth hormone (GH) secretagogues are synthetic molecules with neuroendocrine but also cardiovascular activities mediated by specific GH secretagogue-receptors.

Who Took Part

The abstract describes 24 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, men only.

How the Study Was Run

In design terms this was a placebo-controlled study.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

Left ventricular ejection fraction, left ventricular end diastolic volume, cardiac index and cardiac output were evaluated by intraoperative omniplane transoesophageal echocardiography while wedge pressure, central venous pressure, mean arterial pressure and systemic vascular resistance index were evaluated by systemic and pulmonary arterial catheterization.

What Was Measured

PubMed files the paper under topics including Analysis of Variance, Coronary Artery Bypass, Coronary Artery Disease, Growth Hormone, Growth Hormone-Releasing Hormone, Oligopeptides and Statistics, Nonparametric.

What This Means in Plain Language

The paper is a placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2002 (European journal of pharmacology), a journal based in Netherlands.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Hexarelin: A potent synthetic hexapeptide GH secretagogue, also studied for direct heart effects via the CD36 receptor.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.